An Update on Betrixaban, the Challenging Anticoagulant Agent for Extended Venous Thromboembolism Prophylaxis.

Abstract

Venous thromboembolism (VTE), comprising deep-vein thrombosis (DVT) and pulmonary embolism (PE), stands as the third leading cause of vascular-related mortality on a global scale. Anticoagulation prophylaxis undeniably ensures a significant reduction in the risk of DVT, while simultaneously exposing individuals to an elevated likelihood of experiencing both major and minor bleeding events. Betrixaban is a novel oral anticoagulant, a direct factor Xa inhibitor, approved by the Food and Drug Administration (FDA) but not by the European Medicines Agency (EMA) for VTE thromboprophylaxis. The current necessity revolves around the acquisition of a substantial volume of data to dispel the uncertainties associated with this drug due to its non-approval by the EMA. Consequently, we eagerly await the results of post-marketing pharmacovigilance efforts to provide further insights into the performance of betrixaban within the broader population.